NCT03892421View on ClinicalTrials.gov

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

January 30, 2021

Study Completion Date

April 30, 2021

Conditions
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
Interventions
DRUG

Rituximab

Rituximab 375 mg/m²

DRUG

Carboplatin

Carboplatin AUC5

DRUG

Cytarabine Injection

Cytarabine 2000 mg/m² qd 2 days

DRUG

Dexamethasone

Dexamethasone 40 mg

DRUG

Filgrastim 0.3 MG/ML

One subcutaneous injection daily for 5 days

Trial Locations (1)

02990

Hospital Especialidades Centro Medico La Raza, Mexico City

Sponsors
All Listed Sponsors
lead

La Raza Medical Center

OTHER